
BIOGRAPHICAL SKETCH

NAME: Federico Bussolino

POSITION TITLE: Professor of Biochemistry -University of Torino

DATE AND PLACE OF BIRTH: [REDACTED] Torino (Italy)

WORK ADDRESS: Department of Oncology- sp. 142, Km 3.95 10060 Candiolo

☎: +390119933347

✉: federico.bussolino@unito.it**EDUCATION AND TRAINING (DEGREES)**

Duration (from/to)	Degree and Field of study	Institution	Supervisor/ Mentor	City	Country
Nov 1980/ Oct 1985	Specialization in Nephrology - Immunopathology of kidney diseases	Università di Torino	Vercellone Antonio	Torino	I
Nov 1973/ Feb 1980	MD - Immunopathology and Nephrology	Università di Torino	Camussi Giovanni	Torino	I
Sep 1976/ Jun 1978	Visiting Febrary Inflammation	INSERM U200	Bach Francois	Paris	F

Duration	Position	Institution	City	Country
Oct 2021- Sept 2024	Director of Department of Oncology	Università di Torino	Torino	I
Jan 2013- Sept 2019	Deputy Rector for translational research	Università di Torino	Torino	I
Nov 2017- Sept 20121	Director of Department of Oncology	Università di Torino	Torino	I
January 2014- November 2015	Visiting Professor	Humanitas University	Milano	I

Nov 2002- Present	Chair of the PhD Programme "Complex systems in life sciences" (Former: Complexity in post-genomic biology)	Università di Torino	Torino	I
Dec 1994- Present	Professor of Biochemistry-- Medical School.	Università di Torino	Torino	I
Jan 2009- Apr 2012	Scientific Director	IRCC Candiolo -- Fondazione Piemontese per la Ricerca sul Cancro Onlus (FPRC)	Torino	I
Jan 2007/- Dec 2009	President of the Evaluation Board	Università di Torino	Torino	I
April 2002- Oct 2006	Member of the Evaluation Board	Università di Torino	Torino	I
Nov 2002- Oct 2007	Director of the Department of Oncological Sciences.	Università di Torino	Torino	I
Mar 1991- Nov 1994	Assistant Professor	Università di Torino	Torino	I
Nov 1985- Feb 1991	Post-doc	Università di Torino	Torino	I
Oct 1984- Sep 1985	Visiting	ETH	Zurich	CH
Feb 1983- Oct 1983	Visiting	Erfurt University	Erfurt	D

A. Research Performance

H index –Web of Science: 74; >19600 citations (without auto-citations).

H index Scopus: 73; >21000 (without auto-citations)

H index Google Scholar : 87 ; >30000

orcid.org/0000-0002-5348-1341

Patents:

- F. Bussolino, S. Marchio (2003). A novel mechanism of HIV-1 entry into host cells and peptides inhibiting this mechanism. 02020649.6, Università di Torino
- F. Bussolino, S. Marchio (2006). Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche. PCT/EP2007/010428, Università di Torino
- Marchiò S, Bussolino F (2012). Inhibitors of alpha 6/ E cadherin complex. EP12182994, Università di TorinoFondazione Piemontese per la Ricerca sul Cancro-ONLUS

Awards:

- 2004- Lega Italiana Contro i Tumori

- 2014- Accademia dei Lincei- Award Luigi Feltrinelli

B. Leadership

Co-founder of 2 SMEs. Chair of the Department of Oncological Sciences (2003-2007) and Scientific Director of Institute for Cancer Research at Candiolo (2009- 2012). Co-founder of PhD Programme: Complex Systems in Life Sciences aimed at implementing cross-activities between Biologists, MDs, Physics, Computer scientists. President of the “Evaluation Board” of the University of Torino (2007-2009); President of the Evaluation Committee nominated by the University Ministry for the national professorship selection in Biochemistry (Nov 2016-Oct 2018).

C. Personal Statement

My expertise in tumor angiogenesis and in understanding the cellular and molecular circuits occurring between cancer and stroma cells have been developed over three decades. I have led national and international projects on vascular development, on tumor angiogenesis, fibrosis and the microenvironment. In my own research I have concentrated on the molecular and cellular mechanisms involved in the role of vasculature in tumor progression and metastatic spreading, by focusing on how oncogenic hits impact on the angiogenic mechanisms characterizing singular tumor subtypes and contributing to the onset of acquired resistance to anti-angiogenic regimens. My major interest is in driving the field of the microenvironment in tumor biology forward technically and conceptually. In particular, I’m absolutely convinced that significant progresses in cancer fight, including the route of therapeutic personalized approaches, have to consider cancer as a tissue characterized by cells generally carrying somatic mutations and stroma cells, which differently interact with cancer cells and dynamically influence their behaviour in the host. My research program has been characterized by innovation and thoroughness. I have considerable experience in administering projects with collaborations and co-authored publications. I have also put considerable effort into mentoring young scientists and have trained more than 60 students and postdoctoral fellows. We have developed and used a variety of new technologies and models ranging from molecular biology to genetically engineered mouse models, to high-tech microscope approaches, to network analysis and 3D culture models. Now, my Lab is moving to single cell transcriptomics.

D. Positions and Honors (partial list)

Professional activities

1998 Chair of the Task Force of the Ottolenghi Foundation (Torino) to organize an Institute for Neuroscience Research;

1999-2008: Chair of Molecular Angiogenesis Division at Institute for Cancer Research and Treatment (University of Torino);

2001-2005 Member of the Board of International School of Advanced Study of University of Turin;

2003-2007: Member of the Scientific Board of “Associazione per lo sviluppo scientifico e tecnologico del Piemonte (ASP)”

2004-2008: Member of Scientific Board of Italian Society of Cancerology

2010.-2012 Member of the Scientific Board of Armenise Foundation (Boston)

2010-2015: Member of the Scientific Board of Italian Society of Biochemistry and Molecular Biology

Editorial Boards

2007-present: Associated Editor of Angiogenesis

2007-2010: member of the Editorial Board of Circulation Research

2012-2018: member of the Editorial Board of Arteriosclerosis, Thrombosis and Vascular Biology

E. Industrial appointments

2002: Co-Founder of Creabilis Therapeutics

2007: Co- Founder of Apavadis Biotechnology

F. Contributions to Science (selected) (Paper with > 200 citations are indicated)

1. I contributed to create the groundwork for the role of endothelial cells in inflammation and innate immunity. This includes the elucidation of paracrine and autocrine circuits between inflammatory cytokines (IL-1, IL-6, TNF α) in activating a pro-thrombotic and a pro-inflammatory program changing the surface properties of endothelial cells with the final result to recruit different subsets of leukocytes at site of tissue injuries including tumors.

- a) Bussolino F, Breviario F, Tetta C, Aglietta M, Mantovani A, Dejana E. Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. *J Clin Invest.* 1986 Jun;77(6):2027-33. (258 citations)
- b) Bussolino F, Camussi G, Aglietta M, Braquet P, Bosia A, Pescarmona G, Sanavio F, D'Urso N, Marchisio PC. Human endothelial cells are target for
- c) Bussolino F. Platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. *J Immunol.* 1987 Oct 1;139(7):2439-46. (209 citations)
- d) Bussolino F, Camussi G, Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. *J Biol Chem.* 1988 Aug 25;263(24):11856-61. (201 citations)
- e) Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. *J Exp Med.* 1987 Nov 1;166(5):1390-404. (383 citations)
- f) Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. *Immunol Today.* 1997 May;18(5):231-40 (602 citations).

2. In the 80' the current think was that hematopoiesis was governed by molecules that specifically and exclusively acted on precursors. I contributed to dismantle this dogma showing the vascular properties of colony stimulating factors (G-CSF, CM-CSF). After 25 years the proangiogenic roles of these molecules clarify their fundamental role in the fitness of bone marrow vascular niche.

- a) Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, Aglietta M, Arese P, Mantovani A. Granulocyte- and granulocyte-macrophage-colonystimulating factors induce human endothelial cells to migrate and proliferate. *Nature.* 1989 Feb 2;337(6206):471-3 (550 citations)
- b) Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC, Mantovani A. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. *J Clin Invest.* 1991 Mar;87(3):986-95 (253 citations).
- c) Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. *FASEB J.* 2002 Feb;16(2):225-7.

- d) Soldi R, Primo L, Brizzi MF, Sanavio F, Aglietta M, Polentarutti N, Pegoraro L, Mantovani A, Bussolino F. Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor. *Blood*. 1997 Feb 1;89(3):863-72.

3. I was the first to propose that HGF/MET axis regulates the angiogenic properties of tumor vascular capillaries thus contributing to characterize the cancer invasive program triggered by this couple of ligand-receptor.

- a) Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM, Bussolino F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. *J Immunol*. 1997 Feb 1;158(3):1302-9.
- b) Silvagno F, Follenzi A, Arese M, Prat M, Giraudo E, Gaudino G, Camussi G, Comoglio PM, Bussolino F. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. *Arterioscler Thromb Vasc Biol*. 1995 Nov;15(11):1857-65.
- c) Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. *J Cell Biol*. 1992 Nov;119(3):629-41. (1068 citations)

4. In 1996 I successfully coordinated a grant on angiogenesis funded by EU and I started to work on VEGFs. I showed that HIV-1 Tat activates VEGFR-2 and promotes angiogenesis, an important observation for HIV-associated tumors. It was one of the first demonstration of the partial specificity of VEGF receptors for the ligands belonging to VEGF family. This concept was further extended on VEGFR-1 showing that HIV-1 Tat regulates the recruitment of monocytes in inflamed tissues and the motility of Burkitt lymphoma cells by triggering VEGFR-1. Furthermore the demonstration that HIV-1-Tat activated angiogenesis gave a relevant boost in understanding the mechanisms of epidemic Kaposi's sarcoma. A second and seminal contribution was the demonstration for the first time that the functions of VEGFR-2 in vascular cells are regulated by co-receptors. I reported that α v- β 3 integrin forms a hetero-complex with VEGFR-2, and positively enhances the catalytic and biological function of VEGFA/VEGFR-2 axis.

- a) Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. *Nat Med*. 2002 Mar;8(3):225-32 (201 citations).
- b) Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of α v β 3 integrin in the activation of vascular endothelial growth factor receptor-2. *EMBO J*. 1999 Feb 15;18(4):882-92 (436 citations).
- c) Mitola S, Sozzani S, Luini W, Primo L, Borsatti A, Weich H, Bussolino F. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. *Blood*. 1997 Aug 15;90(4):1365-72.
- d) Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. *Trends Biochem Sci*. 1997 Jul;22(7):251-6. (339 citations).
- e) Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. *Nat Med*. 1996 Dec;2(12):1371-5. (302 citations).

5. Our studies exploiting phage display technology allowed identifying new molecules involved in the interactions between stroma and cancer cells in colorectal cancer. These studies laid the groundwork for thinking about new mechanisms to target tumor metastatization.

- a) Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, Di Nicolantonio F, Marchiò S. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. *Clin Cancer Res*. 2016 Oct 1;22(19):4923-4933
- b) Marchiò S, Soster M, Cardaci S, Muratore A, Bartolini A, Barone V, Ribero D, Monti M, Bovino P, Sun J, Giavazzi R, Asioli S, Cassoni P, Capussotti L, Pucci P, Bugatti A, Rusnati M, Pasqualini R, Arap W, Bussolino F. A complex of $\alpha 6$ integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. *EMBO Mol Med*. 2012 Nov;4(11):1156-75.
- c) Soster M, Juris R, Bonacchi S, Genovese D, Montalti M, Rampazzo E, Zaccheroni N, Garagnani P, Bussolino F, Prodi L, Marchiò S. Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer. *Int J Nanomedicine*. 2012;7:4797-807.

6. We contributed to shape the concept that vascular architecture is regulated by the same molecules that define the trajectories of axons in central and peripheral nervous systems. In particular we described the first endogenous mechanism of inhibition of integrin function analyzing the role of the axon guidance cue semaphorin 3A in vascular system. Both in vascular development and in tumor angiogenesis semaphorins and more in general axon guidance cues play a significant role in vascular maturation and stabilization and represent druggable targets in cancer preclinical models. Furthermore these findings have contributed to open a new vision on how exploit anti-angiogenic regimens in clinical oncology based on the concept of vascular normalization. During the treatment with anti-angiogenic compounds there is a temporal window during the which the chaotic architecture of tumor capillaries normalizes with subsequent improvement of drug delivery and oxygenation. This phenomenon can be used to improve the efficacy of other therapies, reduce the dosages and the subsequent adverse effects.

- a) Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, Bussolino F, Serini G, Giraudo E. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. *J Clin Invest*. 2012 May;122(5):1832-48.
- b) Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, *Bussolino F, Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. *J Clin Invest*. 2009 Nov;119(11):3356-72.
- c) Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Püschel AW, Bussolino F. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. *Nature*. 2003 Jul 24;424(6947):391-7 (393 citations)
- d) Bottos A, Destro E, Rissone A, Graziano S, Cordara G, Assenzio B, Cera MR, Mascia L, *Bussolino F, Arese M. The synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions. *Proc Natl Acad Sci U S A*. 2009 Dec 8;106(49):20782-7
- e) Comunanza V, Corà D, Orso F, Consonni FM, Middonti E, Di Nicolantonio F, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F. VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. *EMBO Mol Med*. 2017 Feb;9(2):219-237.

- f) Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, *Bussolino F, Bardelli A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. *Proc Natl Acad Sci U S A.* 2012 Feb 7;109(6):E353-9.

G. Last relevant publications (2014-2019)

- 1: Bironzo P, Reale ML, Sperone T, Tabbò F, Caglio A, Listì A, Passiglia F, DiMaio M, Righi L, Bussolino F, Scagliotti GV, Novello S. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. *Cancers (Basel).* 2021 May 17;13(10):2425. doi: 10.3390/cancers13102425.
- 2: Pontemezzo E, Foglio E, Vernucci E, Magenta A, D'Agostino M, Sileno S, Astanina E, Bussolino F, Pellegrini L, Germani A, Russo MA, Limana F. miR-200c-3p Regulates Epithelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1. *Int JMol Sci.* 2021 May 7;22(9):4971. doi: 10.3390/ijms22094971.
- 3: Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, Righi L, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, Gigliotti C, Bussolino F, Comunanza V, Guerrera F, Sandri A, Leo F, Libener R, Aviles P, Novello S, Taulli R, Scagliotti GV, Riganti C. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. *Cancers (Basel).* 2021 May 12;13(10):2332. doi: 10.3390/cancers13102332.
- 4: Doronzo G, Astanina E, Bussolino F. The Oncogene Transcription Factor EB Regulates Vascular Functions. *Front Physiol.* 2021 Apr 12;12:640061. doi:10.3389/fphys.2021.640061.
- 5: Cencioni C, Comunanza V, Middonti E, Vallariello E, Bussolino F. The role of redox system in metastasis formation. *Angiogenesis.* 2021 Apr 28. doi:10.1007/s10456-021-09779-5
- 6: Ciccarese F, Grassi A, Pasqualini L, Rosano S, Noghero A, Montenegro F, Bussolino F, Di Camillo B, Finesso L, Toffolo GM, Mitola S, Indraccolo S. Genetic perturbation of IFN- α transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis. *Comput Struct Biotechnol J.* 2020 Dec 2;18:3977-3986. doi: 10.1016/j.csbj.2020.11.048.
- 7: Astanina E, Bussolino F, Doronzo G. Multifaceted activities of transcription factor EB in cancer onset and progression. *Mol Oncol.* 2021 Feb;15(2):327-346. doi: 10.1002/1878-0261.12867.
- 8: Qiu Y, Maione F, Capano S, Meda C, Picconi O, Brundu S, Pisacane A, Sapino A, Palladino C, Barillari G, Monini P, Bussolino F, Ensoli B, Sgadari C, Giraud E. HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. *Mol Cancer Ther.* 2020 Dec;19(12):2476-2489.
- 9: Rosano S, Corà D, Parab S, Zaffuto S, Isella C, Porporato R, Hoza RM, Calogero RA, Riganti C, Bussolino F, Noghero A. A regulatory microRNA network controls endothelial cell phenotypic switch during sprouting angiogenesis. *Elife.* 2020 Jan 24;9:e48095. doi: 10.7554/eLife.48095.

- 10: Cannito S, Foglia B, Villano G, Turato C, Delgado TC, Morello E, Pin F, Novo E, Napione L, Quarta S, Ruvoletto M, Fasolato S, Zanus G, Colombatto S, Lopitz-Otsoa F, Fernández-Ramos D, Bussolino F, Sutti S, Albano E, Martínez-Chantar ML, Pontisso P, Parola M. SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1 α and -2 α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. *Cancers (Basel)*. 2019 Dec 4;11(12):1933. doi:
- 11: Pupo E, Avanzato D, Middonti E, Bussolino F, Lanzetti L. KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer. *Front Oncol*. 2019 Aug 30;9:848. doi: 10.3389/fonc.2019.00848. PMID: 31544066; PMCID: PMC6730590.
- 12: Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, Comunanza V, Alexa-Stratulaf T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C. Wnt/IL-1 β /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. *Int J Cancer*. 2019 May 20. doi: 10.1002/ijc.32419.
- 13: Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardisson F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2019 Aug;14(8):1458-1471.
- 14: Doronzo G, Astanina E, Corà D, Chiabotto G, Comunanza V, Noghero A, Neri F, Puliafito A, Primo L, Spampinato C, Settembre C, Ballabio A, Camussi G, Oliviero S, Bussolino F. TFEB controls vascular development by regulating the proliferation of endothelial cells. *EMBO J*. 2019 Feb 1;38(3).
- 15: Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczyński E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis*. 2018 Aug;21(3):425-532.
- 16: Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leigh N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. *ESMO Open*. 2017 Jan 3;1(6):e000118.

- 17: Comunanza V, Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. *Front Cell Dev Biol.* 2017 Dec 7;5:101. doi:10.3389/fcell.2017.00101.
- 18: Gagliardi PA, Somale D, Puliafito A, Chiaverina G, di Blasio L, Oneto M, Bianchini P, Bussolino F, Primo L. MRCK α is activated by caspase cleavage to assemble an apical actin ring for epithelial cell extrusion. *J Cell Biol.* 2018 Jan 2;217(1):231-249.
- 19: Cora' D, Re A, Caselle M, Bussolino F. MicroRNA-mediated regulatory circuits: outlook and perspectives. *Phys Biol.* 2017 Jun 6;14(4):045001. doi: 10.1088/1478-3975/aa6f21. Review. PubMed PMID: 28586314.
- 20: Comunanza V, Corà D, Orso F, Consolmi FM, Middonti E, Di Nicolantonio F, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F. VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. *EMBO Mol Med.* 2017 Feb;9(2):219-237.
- 21: Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, Di Nicolantonio F, Marchiò S. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. *Clin Cancer Res.* 2016 Oct 1;22(19):4923-4933
- 22: Bartolini A, Di Paolo D, Noghero A, Murgia D, Sementa AR, Cilli M, Pasqualini R, Arap W, Bussolino F, Ponzoni M, Pastorino F, Marchiò S. The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients. *Cancer Res.* 2015 Oct 15;75(20):4265-71.
- 23: Seano G, Chiaverina G, Gagliardi PA, di Blasio L, Puliafito A, Bouvard C, Sessa R, Tarone G, Sorokin L, Helley D, Jain RK, Serini G, Bussolino F, Primo L. Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. *Nat Cell Biol.* 2014 Oct;16(10):931-41, 1-8. doi: 10.1038/ncb3036.

Complete list of my published work in PubMed: <https://www.ncbi.nlm.nih.gov/offcampus.dam.unito.it/pubmed/?term=Bussolino+F+%5Bauthor%5D>

H. Major contributions to early careers of excellent researchers

- Sara Zanivan: PhD in my lab, then Post-doc in Mann' Lab (Max-Planck Institute of Biochemistry), now PI at Beatson Institute (Glasgow)
- Ilaria Cascone: PhD in my lab, then Post-doc in Camonis Lab (Institut Curie, Paris), now Associated Professor. Université Paris Est (F)
- Enrico Giraudo: PhD in my lab, then Post-doc in Hanahan Lab (UCSF at San Francisco), now Associated Professor at Department of Pharmacy, University of Torino
- Marco Arese: PhD in my lab, then Post-doc in Griffin Lab (NYU in New York), now Associated Professor Department of Oncology, University of Torino
- Mattia Pelizzola: PhD in my lab, then Post-doc in Yale University, now Team Leader at Istituto Italiano di Tecnologia (Genova, I)
- Andrea Picco: PhD in my Lab, now assistant professor at the Department of Biochemistry-University of Geneva (CH)

Giorgio Seano: PhD Student in my Lab, now PI at Marie Curie Institute (Paris).
Luca Primo: Post-doc in my Lab, now Professor at Department of Oncology, University of Torino
Stefania Mitola: Post-doc in my Lab, now Professor at Department of Biomedical Sciences, University of Brescia
Alberto Rissone: PhD Student in my Lab, now post doc at NIH, Genetics Molecular Biology Branch (Bethesda)
Simona Pavan: PhD Student in my Lab, now post doc at Department of Biomedicine, University of Basel (CH).
Davide Corà: Post-doc in my Lab, now Associated Professor in Molecular Biology, University A.Avogadro (Novara)